{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 43,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide uses a structured list format to define the target market and unmet medical need.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/10",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Undifferentiated Pleomorphic Sarcoma - StatPearls - NCBI Bookshelf (nih.gov); Annals of Oncology 30: 1143-1153, 2019; Company estimates; Product USPIs; https://www.cancernetwork.com/view/bone-sarcomas. https://rarediseases.org/rare-diseases/liposarcoma/; https://www.sciencedirect.com/science/article/pii/S0923753419386727. ORR, objective response rate (best objective response as confirmed complete response or partial response); STS, soft tissue sarcoma; UPS, undifferentiated pleomorphic sarcoma.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96fb805c-9544-431b-96e2-dc14c697560e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.1,
        "y": 0.54
      },
      "kind": "list",
      "text": "Osteosarcoma - most common malignant primary bone tumor (30% of all such malignancies); Liposarcoma - one of the largest soft tissue sarcoma subtypes (15% - 20% of all STS); Synovial sarcoma - smaller subtype, but high recurrence rate (~50% of patients); Limited effective treatment options across all sarcoma subtypes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16726913-6054-4ea3-a5d7-ceae3ccc969f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.52,
        "y": 0.26
      },
      "kind": "list",
      "text": "Chemotherapy, chemoradiation or regional limb therapy for unresectable cases; No approved therapies specifically for UPS; Approved treatments for sarcoma ORR ~15%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74437f7a-3d06-4a53-90b4-21cc97ef1f87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.13,
        "y": 0.21
      },
      "kind": "list",
      "text": "2nd most common Soft Tissue Sarcoma (STS) subtype (~15% of all STS); High-grade aggressive subtype with high recurrence rates; 3k – 4k AXL+ addressable patients per year in the U.S.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e450fa6-f92a-4fa8-b271-479c19fabe5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Potential market opportunity in sarcoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d987a1c9-5c84-4c49-ade4-c46da398aefd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "edbbf985-fe92-4c38-b710-dd8e2b17be5e",
      "evidence": "2nd most common Soft Tissue Sarcoma (STS) subtype (~15% of all STS); High-grade aggressive subtype with high recurrence rates; 3k – 4k AXL+ addressable patients per year in the U.S.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "133082c7-85f5-4973-804e-0345a7f317eb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck provides market sizing data for various tumor types",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    },
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "2e84312e-7551-4fe1-b34e-202074eadb7a",
      "evidence": "The deck presents market sizing data for various tumor types",
      "position": 1,
      "objective": "What are the potential market opportunities for CAB technology?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}